Inside the race to cure cancer: ‘We're at the cusp of a golden era of treatment'
Although one in two people will get cancer in their lifetime, and there are 385,000 cancer diagnoses each year in the UK, Powis believes that 'we are at the cusp of a golden era in terms of the way we treat a range of cancers … for many cancers now, people should be confident that it's not a death sentence.'
Hayley Brown, science engagement manager at Cancer Research UK, agrees. 'In the 1970s, only one in four people survived cancer for 10 years or more, now it's two in four,' she says. 'More and more people are surviving with fewer side effects and we can see the day coming closer when we can all live free from the fear of cancer.' Brown says that one of the biggest breakthroughs has been the development of cancer vaccines, which are set be rolled out to 10,000 patients on the NHS over the next five years.
'Doctors and scientists have been working on cancer vaccines for decades, but they've now reached a point where they're seeing real promise in boosting survival rates for skin, bowel, lung, brain and pancreatic cancers,' says Brown. 'The vaccines currently being trialled have been developed using the same technology as the Covid vaccine.'
Some, such as LungVax, are preventative and are given to patients identified as being at high-risk of developing the disease. Others, such as a melanoma vaccine, are given to patients who have already been diagnosed with cancer to prevent its recurrence.
Science fiction is now a reality
But they're not a one-size-fits-all anti-cancer shot. A sample of a patient's tumour is removed during surgery, followed by DNA sequencing of the sample using AI. This information is used to make a custom-built jab, specific to the patient's tumour. It primes the immune system to look for cancerous cells and destroy them, with fewer side effects than chemotherapy.
'This is one of the most exciting things we've seen in a really long time,' says Dr Heather Shaw, the national coordinating investigator for the trial of the melanoma vaccine, the first dose of which was delivered at UCLH in 2024. 'This is a really finely honed tool. To be able to sit there and say to your patients that you're offering them something that's effectively like cordon bleu dining versus McDonald's.'
Brown also points to CAR-T therapy which is revolutionising the treatment of blood cancers, which often affect children and young people. This involves collecting T-cells from a patient's blood, genetically modifying them to produce proteins which can recognise and destroy cancer cells, and then putting the improved immune cells back into the patient. 'Our researchers are taking drugs and techniques that once seemed like science fiction and making them a reality,' says Brown.
It's well known that early detection of many cancers dramatically improves survival rates, but doing biopsies can be invasive and time consuming. This is why scientists are excited about 'synthetic biopsies' (which force cancer cells to produce biomarkers, making them more easily detectable via PET scans, blood tests and even breathalysers) and 'liquid biopsies' — blood tests which can diagnose cancer by detecting DNA fragments in plasma.
At trials held at the Institute for Cancer Research in South Kensington, a liquid biopsy was able to predict the risk of breast cancer returning three years before any tumours showed up on scans. Meanwhile, researchers at Oregon Health & Science University have developed PAC-MANN, a test which can pick up signs of pancreatic cancer from just one drop of blood. Eat your heart out, Elizabeth Holmes.
Stopping cancer before it starts
Traditional cancer therapies have been long and arduous, but pioneering, ultra-fast treatment options are on the horizon. 'New drugs and approaches are making treatment more convenient and accessible for patients,' says Dany Bell, strategic adviser for cancer care at Macmillan Cancer Support.
Earlier this year, the NHS announced it would be the first health service in Europe to offer cancer patients a quick injection of the immunotherapy drug nivolumab. This so-called 'super jab' only takes five minutes, compared to an IV drip which takes up to an hour.
'Some immunotherapy now comes in tablet form or can be self-injected at home,' says Bell. Meanwhile, at Cern in Switzerland, they've developed Flash, a way of delivering radiation therapy with fewer side effects than traditional radiotherapy — and it takes less than a second.
Technology is not only being used to identify and treat cancer faster than ever before, it can even predict its likelihood of happening in the first place. MIT scientists have developed an AI learning model called 'Sybil' which can forecast a person's likelihood of developing lung cancer up to six years in advance.
AI models are also being used to create algorithms which look for patterns in a person's behaviour to detect early warning signs for a person's risk of developing cancer.
So how soon will we be able to say we've cured the Big C? Brown points out we're already seeing the benefits of preventative measures brought in relatively recently. The NHS is on track to end cervical cancer by 2040 thanks to the HPV vaccine introduced in 2008. 'Beating cancer won't come from one silver bullet, but combinations of these breakthroughs and treatments and preventions,' says Brown. 'There's a lot of hope.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Yellow heat health alert issued for southern half of England
A yellow heat health alert has been issued across much of England for the start of next week as a new wave of warm weather sweeps in. The warning, issued by the UK Health Security Agency (UKHSA), covers London, Yorkshire and the Humber, East Midlands, East of England, the South East and South West, and will be in place from 12pm on Monday until 6pm on Wednesday. Significant impacts across health and social care services may occur over the period due to the high temperatures, the agency said. This includes the potential for a rise in deaths, particularly among those aged 65 and over or with health conditions. The latest warning comes after the UK has already experienced three heatwaves this summer. A combination of amber and yellow heat health warnings were issued across England last month when temperatures exceeded 30C in several parts of the country.
Yahoo
an hour ago
- Yahoo
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma ('the Company' or 'Nxera'; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2025. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented: 'Nxera continued to make good progress in the first half of 2025. We are seeing increasing revenues from sales of PIVLAZ® and QUVIVIQ®, our marketed products in Japan, as well as notable progress across our partnered programs, with multiple programs advancing through clinical development and reaching important revenue-bearing milestones. This includes NBI-'568 – being advanced by Neurocrine – which is the first candidate designed using Nxera technology to enter Phase 3 trials. Using our NxWave™ platform, these candidates are designed to address areas of significant and increasing medical need across our key therapeutic focus areas of obesity and metabolic disorders, neurology/neuropsychiatry, and immunology and inflammation. In addition, we continue to make progress advancing our inhouse pipeline of novel candidates. Moving into the second half of 2025, we anticipate further key data readouts from multiple clinical trials and with several new studies due to commence, we are well positioned to deliver significant value for patients and shareholders.' Operational Highlights for Q2 2025 Progress with marketed products in Japan The Group sells PIVLAZ® (clazosentan sodium 150mg) for the prevention of cerebral vasospasm in Japan using its in-house salesforce. PIVLAZ® revenue increased from JPY 5,393 million to JPY 5,805 million (up by 7.6% vs the prior corresponding period) The Group earns royalty revenue on sales of QUVIVIQ® (daridorexant 25 and 50 mg) by Shionogi & Co., Ltd. ('Shionogi'), as well as revenue on the supply of QUVIVIQ® to Shionogi. This amounted to JPY 1,586 million for the first half 2025. As sales of QUVIVIQ® began in the fourth quarter of the prior year, there were no sales for the prior corresponding period Progress with partnered programs Neurocrine Biosciences dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-'568), resulting in a payment of US$15 million to the Company NBI-'568 is an oral, selective muscarinic M4 receptor agonist The Phase 3 study is a global double-blind, placebo-controlled trial evaluating NBI-'568 in adults with a primary diagnosis of schizophrenia who are experiencing an acute exacerbation or relapse of symptoms The study is expected to enroll approximately 280 patients. The primary endpoint of the study is a reduction from baseline in the Positive and Negative Syndrome Scale (PANSS) The key secondary endpoint is improvement in the Clinical Global Impression of Severity (CGI-S) scale Development milestone achieved under the multi-target collaboration and license agreement with Eli Lilly and Company targeting diabetes and metabolic diseases, resulting in a payment to the Company US$4.8 million milestone payment received from Centessa Pharmaceuticals (UK) Limited ('Centessa') as a result of Centessa initiating clinical development of ORX142 ORX142 is Centessa's second investigational, novel, highly potent and selective OX2R agonist discovered using Nxera technology and being developed for the treatment of select neurological and neurodegenerative disorders The milestones were achieved as Centessa first received clearance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for a Phase 1 clinical study of ORX142 in healthy volunteers and second, with the initiation of the study The payment receipt was fully recognized as revenue in the second quarter of 2025 Post-period events Nxera launched a broad proprietary pipeline targeting obesity and chronic weight management Independent of our productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in obesity and associated metabolic disorders Central to this pipeline is Nxera's new, wholly-owned oral small molecule GLP-1 agonist program, focused on differentiated chemistry, which is distinct, independent and developed separately from Pfizer's PF-06954522, allowing Nxera full control to drive rapid progress Complementing this program, Nxera is simultaneously accelerating the advancement of an additional six established GPCR-targeted programs focused on obesity and chronic weight management Pfizer discontinued development of its Phase 1 candidate PF-06954522 (a small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera) due to a portfolio decision by Pfizer Financial Highlights for the Six-month Period ended 30 June 2025 Revenue totalled JPY 15,094 million (US$101.6 million*), an increase of JPY 2,374 million (US$18.0 million) vs. the prior corresponding period. This increase was primarily due to the inclusion of sales of QUVIVIQ® following its launch in the fourth quarter of 2024. R&D expenses totalled JPY 7,474 million (US$50.3 million), an increase of JPY 1,987 million (US$14.2 million) vs. the prior corresponding period. This increase primarily reflects an increased investment in R&D and the impact of the weaker Yen. SG&A expenses totalled JPY 7,566 million (US$51.0 million), a decrease of JPY 456 million (US$1.8 million) vs. the prior corresponding period. This decrease was primarily due to lower selling related costs as a result of targeted cost savings, partially offset by incremental spend on personnel to strengthen organizational capabilities. Operating loss totalled JPY 2,756 million (US$18.5 million) vs. an operating loss of JPY 3,654 million (US$24.0 million) in the prior corresponding period. This change in profitability reflects the combined effect of all movements explained above. Loss before income tax totalled JPY 3,722 million (US$25.1 million) vs. a loss before income tax of JPY 3,158 million (US$20.8 million) in the prior corresponding period. Net loss totalled JPY 3,137 million (US$21.1 million) vs. a net loss of JPY 4,703 million (US$30.9 million) in the prior corresponding period. Core operating profit** totalled JPY 364 million (US$2.5 million) vs. a core operating profit of JPY 1,176 million (US$7.7 million) in the prior corresponding period. Cash and cash equivalents as at 30 June 2025 amounted to JPY 32,997 million (US$228.1 million) having increased by JPY 729 million (US$22.3 million) from the beginning of the year. *Convenience conversion to US$ at the following rates: FY 2025: 1US$ =148.56 JPY; FY 2024: 1US$ =152.12 JPY; 30 Jun 2025: 1US$ = 144.66 JPY; 31 Dec 2024: 1US$ = 156.83 JPY ** Core operating profit / loss is an alternative performance measure which adjusts for material non-cash costs and one-off costs in order to provide insights into the recurring cash generation capability of the core business. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@ MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@ Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Attachment Nxera Pharma FY25Q2 E_TanshinError while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
‘I'm terrified of the motorway': The midlife women gripped by a driving phobia
Creeping along the slow lane of Britain's motorways, a silent struggle is unfolding, largely unseen and rarely discussed. It is a particular form of anxiety, a 'hidden epidemic' known as amaxophobia – the fear of driving – specifically afflicting a growing number of midlife women. While often dismissed as a mere lack of confidence, for many, this isn't simply a reluctance to merge onto the M25 or navigate the Spaghetti Junction; it is a profound, debilitating phobia that curtails lives, limits opportunities, and chips away at independence. While up to a fifth of us have anxiety about driving, 10 per cent are so nervous it counts as a diagnosable driving phobia. For decades, women have been encouraged to embrace the freedom of the open road, yet for a significant cohort reaching their 40s, 50s and beyond, the motorway has become a psychological barrier as formidable as any physical obstacle. The very thought of the fast lane, of overtaking a large lorry, or being caught in a standstill jam, can trigger panic attacks, cold sweats and an overwhelming desire to stay firmly on familiar A-roads, or indeed, at home. Experts say that amaxophobia, particularly in midlife women, is far more prevalent than statistics suggest, largely because sufferers are often too ashamed or embarrassed to admit their struggle. 'Many women with amaxophobia feel ashamed and alone,' says Tracey Field, who, along with husband Kevin, produces The Driving Confident Podcast. Tracey says the prevalence of amaxophobia in midlife women is significant. 'It is particularly common in women in their 40s and 50s and it is rarely driving that is the root of the problem,' she says. 'Amaxophobia usually starts if we are experiencing high levels of stress – hello midlife! This could be work, finances, health, relationships, it could be looking after children and our elderly parents. As we are thinking about these stressful things we start to feel stressed but as we are driving, we can't problem-solve so we keep thinking. 'Often those feelings develop into feelings of panic or anxiety, so the first panic attack happens on the road, which is terrifying. Our brain then associates the feelings of anxiety with driving. So, the avoidance isn't of driving, the avoidance is trying not to have those feelings again.' But once you're scared of driving – especially on a motorway – is there any way to get your confidence back? Motherhood robbed me of my ability to bomb up and down the motorway I'm one of those midlife women – I'm 47 – for whom driving has been a source of fear. For me, during my 20s as a cub reporter at a national newspaper, the motorways were my professional playground. As a roving news writer, several hundred miles a day was not unusual. I loved hurtling along motorways in my tiny, green Nissan Micra, in pursuit of the next big scoop. My car was an indispensable tool, a mobile office, and a gateway to myriad stories. However, a seismic shift occurred 12 years ago after the birth of my son. What began as mild claustrophobia, a fleeting discomfort in enclosed spaces, spiralled into an 'irrational fear' of motorway driving. I was petrified I would be stranded on a motorway and he would be crying in the back with me unable to comfort him, or that I would somehow lose control and veer us both off the road. It was impossible to manage, and I was furious with myself, ridden with guilt that I couldn't be a 'proper mum'. I worried that if something terrible happened, I might not even be able to drive him to hospital. This wasn't my first brush with panic behind the wheel. In my 20s, a distressing visit to my grandmother in hospital culminated in a terrifying panic attack on a dark, rainy Boxing Day night. Overwhelmed and disoriented, I abandoned my car at the M3's Fleet Services and called my mum to come to the rescue. But that episode was a fleeting blip. It was the advent of motherhood that truly unleashed the beast of anxiety in me. The relentless pressure of parental responsibility, coupled with a newfound vulnerability, created fertile ground for my fear to flourish. For more than 10 years, I endured this silent torment, a prisoner to my phobia and too ashamed to admit it or seek help. Then last year, I forced myself to confront it, not wanting to transfer my anxieties onto my children. I embarked on a series of one-on-one cognitive behavioural therapy (CBT) sessions. Slowly, painstakingly, I began to dismantle the edifice of my fear, brick by anxious brick. I can now drive on motorways alone or with my family, and while it is not with the same gay abandon of my youth, it is with a new confidence that just a few years ago I did not believe was possible. Just last week I completed a 200-mile drive in our family camper van all along the M4 from London to Wales. A major triumph for someone who just a year ago had palpitations at just the thought of completing one junction. Having overcome my phobia, I am now open about what I felt was an irrational fear, and everyone I speak to has a story of someone they know – almost always a midlife woman – who suffers the same. Terrified after a traumatic crash in India Take Amanda Fitzgerald, a 55-year-old Essex-based mother of two grown-up children, who carries the deep scars of a traumatic road incident from her 20s, which cruelly re-emerged as her marriage broke down. While travelling through India with her mother in 1995, their car was unrecognisably mangled when a truck careened into their rear, crumpling the boot and making the passenger doors almost impossible to exit from. 'The car was concertinaed,' she recalls, 'and we were both lucky so have escaped injury-free and not to have been killed instantly.' Miraculously, despite the horrific nature of the crash, Amanda spent years driving without incident or anxiety. The trauma, it seemed, had been relegated to the archives of her memory. However, life has a habit of unearthing buried anxieties. The breakdown of Amanda's marriage in 2018 triggered a delayed reaction, manifesting as a sudden and debilitating panic attack in her car. From that moment on, motorways became anathema, not to mention the sight of lorries in her rear-view mirror. Her fear imposed absurd detours and limitations: a journey to visit see her family mother that should have taken less than three hours stretched to a gruelling six or seven as she opted to 'avoid motorways' on her sat nav, and the simple act of driving down a dual carriageway to collect her daughter became an impossible feat. The sheer thought of motorway driving was enough to trigger overwhelming dread. Faced with such profound disruption to her life, Amanda sought help. She found a driving instructor specifically recommended for his expertise in working with women suffering from amaxophobia. Sessions focused on confronting her deepest anxiety: the looming presence of lorries on motorways. Despite almost suffering a panic attack during one session, the culmination of Amanda's efforts came last month in a defining moment: successfully overtaking a lorry on the M4. It was a small victory, perhaps, but for Amanda, it was a giant leap. When Amanda shared her experience at a TEDx-style event, Speak and Shine, she was shocked to have so many female audience members coming up to her afterwards to confess they too had this hidden fear. As a public relations expert, Amanda presents as the strongest of characters, so to discover that her 'secret shame' echoed mine was a revelation. She told me: 'I'm always encouraging women to put their feet to the fire and do what it takes to make their business a success, but I was afraid of getting my feet anywhere near anything lukewarm; the terror of tackling a motorway was so engulfing. However, I am a firm believer in practising what you preach, so one day I decided to face my fears head-on. I shared my phobia of motorway driving with a friend, who then said she also suffered from amaxophobia, and recommended specialised driving lessons to me.' 'The first time I overtook a lorry during my sessions I felt an overwhelming sense of euphoria,' she says. 'Doing 'on-the-job' training was so important. I felt free and empowered. An incredible feeling of relief.' An M25 meltdown ended in terror For 60-year-old Josephine Pembroke from Chiswick, a stand-up and cabaret performer, the moment her world narrowed to the confines of her vehicle was stark and terrifying. 'It was where the M4 meets the M25,' she recounts, the memory still vivid. 'I was changing lanes and had a meltdown. My arms went stiff, I went dizzy, I could not breathe, I was panicking.' With her 11-year-old son in the back, Josephine found herself in an impossible situation, stopping her car on a tiny island between slip roads on one of the busiest motorways in Europe. 'I was having an anxiety attack. I now know my fear of motorways was amaxophobia.' In a state of extreme distress, Josephine dialled 999. The transport police arrived, and in a surreal turn of events, had to halt all traffic on the M25 side of the road to allow her to crawl at a 'snail's pace' to the hard shoulder. She was then escorted home by the police, driving at an excruciatingly slow speed. The aftermath was equally challenging: her driving licence was confiscated, and she was forced to 'prove that I did not have a serious mental health issue'. Following this harrowing experience, Josephine stopped driving altogether, and her anxiety worsened. But despite the significant setbacks, she is steadily rebuilding her confidence through graded exposure. She can now drive on dual carriageways independently and is committed to gradually building up to motorway driving. However, the sight of the blue motorway sign still triggers 'the jitters' – a lingering reminder of her past ordeal. Josephine's journey underscores the deeply personal and often misunderstood nature of phobias. 'Amaxophobia is just that – a phobia,' she says, 'and phobias by nature are not rational, but this particular phobia is not uncommon, and it needs to be recognised.' The tools to tackle amaxophobia Psychotherapist Lucy da Silva identifies several contributing factors unique to this unique demographic. She says: 'Midlife often brings a confluence of stressors, and these periods of heightened stress can lower a woman's resilience and leave them more susceptible to developing anxieties.' While Amanda's close call was an obvious trigger, Da Silva says that even minor, forgotten incidents – a near miss, a sudden brake, or witnessing a roadside accident – can lodge in the subconscious and resurface as anxiety years later. The good news is that amaxophobia is highly treatable. 'It's not a life sentence,' she assures. 'With the right strategies and support, women can absolutely regain their confidence and freedom.' Key approaches include CBT, and the gradual exposure method of slowly and systematically reintroducing yourself to the feared situation. I started with driving short distances on quiet A roads, then motorways, gradually increasing speed and distance. Many driving schools now offer specific 'motorway confidence' courses with specialist instructors trained to work with anxious drivers, providing a safe, controlled environment to practice and rebuild skills. But most of all, women need to talk about this issue. By opening up about my 'irrational' fear, I found that dozens of other midlife women feel the same. Help is out there; we just need to drive ourselves a little further to find it. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Solve the daily Crossword